Pfizer’s latest $650 million purchase of cancer drugs from Suzhou‑based Innovent Biologics marks the latest wave of U.S. pharma ties to China. The deal could unlock up to $10.5 billion for Innovent if commercial and regulatory milestones are met, tightening the grip of Chinese biotech on Western pipelines for global drug markets and investors who watch the supply chain dynamics closely today.

Congressional pressure mounts as Republican Rep. John Moolenaar urges Treasury to embed biotech in a 2025 national security bill. He cites Bristol Myers Squibb’s $950 million pact with Hengrui and Pfizer’s Innovent deal, warning that U.S. capital flowing into Chinese IP could trigger future restrictions. The U.S. International Trade Commission now probes state support for Chinese biotechs that impacts global pharma.

European giants AbbVie, AstraZeneca, Eli Lilly, Novartis and Sanofi have already shelled out $2.5 billion in cash to Chinese firms for drug assets, excluding equity stakes. Investors like Bellevue’s Kyle Rasbach warn that the Committee on Foreign Investment in the U.S. may block deals if Chinese ownership sits on a regulatory “margin.” The sector faces a tightening risk‑assessment climate for global.